Dr Francesco talks to ecancertv at ASCO 2015 about the data from a study of 720 patient metastatic melanoma patients using ipilimumab 3 mg/kg within the Italian expanded access programme.
By analysing a large cohort of ipilimumab-treated advanced melanoma patients, he identified a subpopulation of patients that is very unlikely to benefit from this treatment.
Based on these data, responders could be easily selected from general population, allowing for upfront screening that could spare toxicity to non-responders.
ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.